Posts tagged #bd&l

Fourteen months ago, I predicted that ADCs would be the most successful drug modality of the 2020s. The deal flow since then has validated that prediction, but the structural-IP layer underneath it reveals where the next deals will originate, not just where the next deals will land.

TYK2's structural-IP layer is the elephant that connects the deal flow, the clinical readouts, the cohort statistics, and the issued-claim records — and reading it requires the kind of methodological discipline the rDNA.ai series has been describing across the post-FOIA BD&L toolkit.

An analysis of the structural-IP layer in the post-2020 CLDN18.2 patent record, read against the backdrop of recent China-originator deal flow and Representative Moolenaar's letter to Treasury Secretary Bessent about the COINS Act.

This is the sixth article in the rDNA.ai biopharma BD&L series. It looks back at the 2017 GLP-1 indication shift through the lens of a back-test of the KC scoring framework, to see what a rigorous IP-quality reading of the pre-2017 patent record would have said about the foundational IP and the eventual indication shift.

The final article in a series about how biopharma BD&L should use the patent record in a post-FOIA world.

The fourth in a five-part series of articles about how biopharma BD&L should use the patent record in a post-FOIA world.

The third in a five-part series of articles about how biopharma BD&L should use the patent record in a post-FOIA world.

The second in a five-part series of articles about how biopharma BD&L should use the patent record in a post-FOIA world.

An introduction to an article series about how biopharma BD&L should use the patent record in a post-FOIA world.